Please login to the form below

Not currently logged in
Email:
Password:

David Khougazian appointed president of Sanofi Pasteur MSD

He will succeed Dr Jean-Paul Kress atthe Sanofi Pasteur - Merck & Co venture

Sanofi Pasteur MSD David KhougazianSanofi Pasteur MSD has appointed David Khougazian as its new president, a role he will take up on September 1, when he will succeed Dr Jean-Paul Kress at the Sanofi Pasteur - Merck  & Co venture.

Kress, who has led the company since July 2011, will then leave Sanofi Pasteur MSD to join the Sanofi group - which recently announced a major restructuring of its business.

Khougazian moves to the vaccines-focused firm from a position as Sanofi CEO chief of staff, which he held since 2011.

Prior to this he had a number of business operations positions in sales and marketing and as general manager, having joined Rhône-Poulenc (now part of Sanofi) in 1997.

Olivier Charmeil, president and CEO of Sanofi Pasteur, said: “Sanofi Pasteur MSD is a major player in the European vaccines market. David's appointment marks a new phase in our development in Western Europe; a challenging and strategic region for our vaccines activity.

“His knowledge of European markets and external stakeholders will be a strong asset to grow Sanofi Pasteur MSD's position in Europe.”

23rd July 2015

From: Research, Sales

Share

Tags

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

Research Partnership, an Inizio Advisory Company, is a world-leading custom and syndicated global insights partner for health and life science...

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...